The DMKN had the highest sensitivity, specificity, and AUC in EMT+ advanced melanoma, suggesting its usability as a marker to effectively predict and diagnose advanced BRAF-mutant and EMT+ melanoma cancer. This evidence concerns the gene BRAF and melanoma.